

[PICTURES IN CLINICAL MEDICINE]


Lymphangi leiomyomatosis Associated with Tuberous Sclerosis Complex

Keizo Tanitame

Key words: lymphangi leiomyomatosis, calcified tuber, renal angiomyolipoma, tuberous sclerosis complex, mammalian target of rapamycin

(Intern Med 59: 2801-2802, 2020)

(DOI: 10.2169/internalmedicine.5116-20)



Picture.

A 31-year-old schizophrenic woman presented to the emergency department with asthma-like dyspnea. Laboratory tests revealed mild anemia, and her room air arterial oxygen saturation by pulse oximetry (SpO₂) was 93%. After receiving

Department of Diagnostic Radiology, Hiroshima Prefectural Hospital, Japan

Received: April 19, 2020; Accepted: June 1, 2020; Advance Publication by J-STAGE: July 14, 2020

Correspondence to Dr. Keizo Tanitame, tntrad@gmail.com

ing bronchodilator drugs, her symptoms improved and the SpO₂ increased to 98%. A subsequently performed computed tomography scan revealed multiple thin walled cysts and increased pulmonary parenchymal attenuation in the bilateral lungs, subependymal (arrows) and cortical (arrowhead) calcification of the brain, and both kidneys were markedly enlarged with normal tissue being replaced by extensive fat-attenuating tissue (Picture). Lymphangioliomyomatosis, calcified tubers, and renal angiomyolipomas associated with tuberous sclerosis complex (TSC) were diagnosed based on the Japanese TSC diagnostic criteria. Her forced expiratory volume in 1 second was 2.08 L (76.4% predicted) after bronchodilator administration. Transcatheter arterial embolization to prevent the onset of hemorrhaging from angiomyolipomas (1) was not performed in consideration of the risk of renal function impairment, but instead treatment with a

mammalian target of rapamycin inhibitor (2) was initiated.

The author states that he has no Conflict of Interest (COI).

References

1. Champagnac J, Melodelima C, Martinelli T, et al. Microaneurysms in renal angiomyolipomas: can clinical and computed tomography features predict their presence and size? *Diagn Interv Imaging* **97**: 321-326, 2016.
2. Habib SL, Al-Obaidi NY, Nowacki M, et al. Is mTOR inhibitor good enough for treatment all tumors in TSC patients? *J Cancer* **7**: 1621-1631, 2016.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (<https://creativecommons.org/licenses/by-nc-nd/4.0/>).